Abstract
It is unclear to what extent the findings of the sodium–glucose co‐transporter‐2 (SGLT‐2) inhibitor cardiovascular outcomes trials (CVOTs) are generalizable to the real‐world type 2 diabetes populations.
Using a national primary care database, we found that the inclusion criteria of four SGLT‐2 inhibitor CVOTs applied to between 7% and 27% of people with type 2 diabetes.
Generalizability of the findings from CVOTs to a wider type 2 diabetes population may be restricted to groups defined by the inclusion criteria for each trial.
Uniform inclusion criteria for trials would allow direct comparison to be made between trials.